Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing
Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related

Vinge advises Dignitana on the public offer from Paxman

 Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025

Vinge has advised Boliden in connection with a directed share issue of SEK 3.75 billion

 Vinge has advised Boliden AB in connection with a directed share issue through which the company raises proceeds of approximately SEK 3.75 billion before transaction costs.
March 21, 2025

Vinge advises EQT on its EUR 890 million sale of Dellner Couplers to Wabtec

 Vinge together with Milbank advises the EQT VIII fund (“EQT”) on its sale of Dellner Couplers (“Dellner”), a leading provider of train connection systems for passenger rail, to Wabtec Corporation (a fortune 500 company listed on the New York Stock Exchange, NYSE: WAB). The transaction values Dellner at approximately EUR 890 million. The transaction is subject to customary conditions and regulatory approvals.
March 19, 2025